Tech Center 1600 • Art Units: 1612 1615 1618
This examiner grants 63% of resolved cases
Celeste A. Roney serves in Art Unit 1612 of Tech Center 1600. With 771 resolved cases, the examiner has established an allowance rate of 62.8 percent. This volume of cases provides a robust statistical foundation for understanding the examiner's prosecution tendencies and decision-making patterns. The 62.8 percent allowance rate indicates a moderate level of difficulty, requiring well-supported arguments to secure a patent grant.
The data indicates an interview lift of 17.5 percent. This positive lift suggests that applicants may find value in requesting interviews to clarify technical points or negotiate claim language, as these interactions are associated with higher allowance probabilities. The 17.5 percent increase in success rate highlights the examiner's willingness to engage in productive dialogue. For practitioners, this means that an interview should be viewed as a standard part of the prosecution strategy rather than an exceptional measure.
The median days to allowance for this examiner is 1104. This timeline offers a predictable window for the duration of the examination process, helping applicants manage their expectations for patent issuance. The 1104-day median is a key metric for strategic planning, especially when coordinating patent filings with product launches or funding rounds. It provides a realistic view of the time commitment required to navigate the 1612 Art Unit's requirements.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18563898 | HALLUCINOGEN-FATTY ACID COMBINATION | Non-Final OA | Mindset Pharma Inc. |
| 18182733 | LIPID COMPOSITION | Final Rejection | FUJIFILM Corporation |
| 17917233 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | Final Rejection | The Regents of the University of California |
| 18283406 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | Non-Final OA | The Board of Regents of the University of Texas System |
| 17497517 | METHODS AND SYSTEMS FOR DETECTING PSYCHOTIC DISORDERS ASSOCIATED WITH SEROTONIN RECEPTOR DEFICIENCIES | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 19066812 | HAIR TREATMENT COMPOSITION | Non-Final OA | L'OREAL |
| 18716488 | COMPOSITION FOR KERATIN FIBERS | Non-Final OA | L'Oreal |
| 18731085 | COMPOSITIONS AND METHODS FOR CARING FOR KERATIN MATERIALS | Final Rejection | L'Oreal |
| 18690391 | MAKEUP KIT COMPRISING AN AQUEOUS MAKEUP COMPOSITION AND A CONTINUOUS OILY-PHASE FIXING COMPOSITION WITH A HYDROPHOBIC FILM-FORMING POLYMER | Final Rejection | L'OREAL |
| 18084403 | COMPOSITIONS AND METHODS FOR REMOVING COLOR FROM HAIR | Non-Final OA | L'Oreal |
| 18252597 | COMPOUNDS FOR THE DETECTION OF HEME OXYGENASE 1 (HO-1), AND METHODS AND USES INVOLVING THE SAME | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18996093 | LOADED EXTRACELLULAR VESICLE | Non-Final OA | Oxford University Innovation Limited |
| 18292042 | METHODS OF TREATING COPPER METABOLISM-ASSOCIATED DISEASES OR DISORDERS | Final Rejection | Alexion Pharmaceuticals, Inc. |
| 18503474 | USES OF BUPIVACAINE MULTIVESICULAR LIPOSOMES AS STELLATE GANGLION BLOCK FOR TREATING ANXIETY DISORDERS AND TRAUMATIC BRAIN INJURY | Final Rejection | Pacira Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy